Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial
A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer's disease and was well tolerated in a Phase I trial. The post Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News .
Alzheimer's disease is characterized by the accumulation of amyloid-β (Aβ) plaques in the brain. Current treatments have shown only limited clinical benefits. Researchers are now exploring new targets, focusing on microglia—the brain's immune cells responsible for clearing debris and maintaining neural networks. A new small molecule therapy, VG-3927, has shown promise in preclinical studies and early human trials.
VG-3927 is an oral, CNS-penetrant small-molecule TREM2 agonist that activates the transmembrane domain of TREM2, promoting higher-order receptor complex formation and downstream signaling. In a Phase I trial involving 115 participants, the therapy was found to be well-tolerated and reached the central nervous system. The study also observed reductions in markers of neuronal damage and inflammatory signaling in treated patients.
Additionally, VG-3927 enhanced the ability of microglia to break down amyloid-beta in a mouse model, suggesting potential therapeutic benefits for Alzheimer's disease.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
